ZVSA · Zyversa Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $57.6K | - | $365.1K | $409.9K | $258.9K | - | $436.0K | $709.0K | $512.9K | - |
| SG&A | $1.25M | - | $1.74M | $1.63M | $1.89M | - | $1.83M | $2.04M | $2.31M | - |
| Total Operating Expenses | $1.30M | - | $20.75M | $2.04M | $2.14M | - | $2.27M | $2.75M | $2.83M | - |
| D&A | - | - | - | - | - | - | - | - | $2.6K | - |
| Operating Income | ($1.30M) | - | ($20.75M) | ($2.04M) | ($2.14M) | - | ($2.27M) | ($2.75M) | ($2.83M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | ($851.7K) | - | - | - | - | $9.7K | - | - |
| Net Income | ($1.79M) | - | ($19.81M) | ($2.21M) | ($2.26M) | - | ($2.40M) | ($2.76M) | ($2.83M) | - |
| EPS - Basic | ($0.22) | - | ($2.56) | ($0.46) | ($0.73) | - | ($2.43) | ($3.31) | ($4.53) | - |
| EPS - Diluted | ($0.22) | - | ($2.56) | ($0.46) | ($0.73) | - | ($2.43) | ($3.31) | ($4.53) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $302.7K | $101.8K | $528.0K | $72.1K | $1.61M | $1.53M | $1.58M | $119.5K | $2.03M | $3.14M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $10.24M | $10.12M | $9.81M | $9.77M | $9.60M | $9.34M | $9.28M | $8.32M | $8.13M | $8.43M |
| Current Assets | $742.2K | $347.9K | $995.5K | $549.1K | $2.11M | $1.72M | $390.4K | $641.4K | $2.90M | $3.35M |
| Total Assets | $742.2K | $347.9K | $1.04M | $19.64M | $20.99M | $20.60M | $19.42M | $19.47M | $21.65M | $22.11M |
| Current Liabilities | $14.87M | $12.73M | $12.77M | $12.69M | $12.00M | $11.23M | $11.54M | $9.99M | $9.58M | $10.19M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $14.87M | $12.73M | $12.77M | $13.54M | $12.86M | $12.08M | $12.40M | $10.85M | $10.43M | $11.04M |
| Stockholders' Equity | ($14.12M) | ($12.39M) | ($11.73M) | $6.10M | $8.13M | $8.52M | $7.03M | $8.62M | $11.22M | $11.07M |
| Retained Earnings | ($139.38M) | ($137.58M) | ($136.91M) | ($117.10M) | ($114.89M) | ($112.63M) | ($111.21M) | ($108.81M) | ($106.05M) | ($103.22M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($799.1K) | - | - | - | ($1.77M) | - | - | - | ($3.78M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $1.00M | - | - | - | $1.85M | - | - | - | $2.67M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -241.6% | - | -1903.9% | -11.3% | -10.8% | - | -12.4% | -14.2% | -13.1% | - |
| Return on equity | 12.7% | - | 168.9% | -36.3% | -27.8% | - | -34.2% | -32.1% | -25.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.05 | 0.03 | 0.08 | 0.04 | 0.18 | 0.15 | 0.03 | 0.06 | 0.30 | 0.33 |
| Quick ratio | 0.05 | 0.03 | 0.08 | 0.04 | 0.18 | 0.15 | 0.03 | 0.06 | 0.30 | 0.33 |
| Cash ratio | 0.02 | 0.01 | 0.04 | 0.01 | 0.13 | 0.14 | 0.14 | 0.01 | 0.21 | 0.31 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.05 | -0.03 | -0.09 | 3.22 | 2.58 | 2.42 | 2.76 | 2.26 | 1.93 | 2.00 |
| Liabilities / Assets | 20.03 | 36.60 | 12.27 | 0.69 | 0.61 | 0.59 | 0.64 | 0.56 | 0.48 | 0.50 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 39.2% | - | -814.3% | 25.8% | 24.1% | - | 21.8% | 96.8% | 38.4% | - |
| Net income growth (YoY) | 20.5% | - | -724.8% | 20.0% | 20.2% | - | 17.3% | 96.5% | 20.2% | - |
| EPS growth (YoY) | 69.9% | - | -5.3% | 86.1% | 83.9% | - | -2600.0% | 31.6% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | -29.2% | -27.6% | -23.1% | -64.3% | -57.0% | -88.4% | -88.9% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ZyVersa Therapeutics against the 5 most active filers in the same SIC group.